Evidence map›Paper›PMID 30714145›Full record

ArticleBritish journal of pharmacology2019

Inhibition of Ca

Elodie Picard, Frederic Antonio Carvalho, Francina Agosti, Emmanuel Bourinet, Denis Ardid, Alain Eschalier, Laurence Daulhac, Christophe Mallet

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Frontiers in microbiology · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Modulation of Recombinant Human T-Type Calcium Channels by ΔCannabis and cannabinoid research · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Targeting T-type/CaV3.2 channels for chronic pain.Translational research : the journal of laboratory and clinical medicine · 2021
    Review
  14. Studying human nociceptors: from fundamentals to clinic.Brain : a journal of neurology · 2021
    Review
  15. Article
  16. Review
  17. Inhibition of CaBritish journal of pharmacology · 2019
    Article
  18. PasteurizedGut microbes
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Elodie PicardUniversité Clermont Auvergne, INSERM, CHU, NEURO-DOL Basics & Clinical Pharmacology of Pain, F-63000 Clermont-Ferrand, France.
Frederic Antonio CarvalhoUniversité Clermont Auvergne, INSERM, CHU, NEURO-DOL Basics & Clinical Pharmacology of Pain, F-63000 Clermont-Ferrand, France.
Francina AgostiCNRS, INSERM, LABEX ICST, IGF, Université Montpellier, Montpellier, France.
Emmanuel BourinetCNRS, INSERM, LABEX ICST, IGF, Université Montpellier, Montpellier, France.
Denis ArdidUniversité Clermont Auvergne, INSERM, CHU, NEURO-DOL Basics & Clinical Pharmacology of Pain, F-63000 Clermont-Ferrand, France.
Alain EschalierUniversité Clermont Auvergne, INSERM, CHU, NEURO-DOL Basics & Clinical Pharmacology of Pain, F-63000 Clermont-Ferrand, France.
Laurence DaulhacUniversité Clermont Auvergne, INSERM, CHU, NEURO-DOL Basics & Clinical Pharmacology of Pain, F-63000 Clermont-Ferrand, France.
Christophe MalletUniversité Clermont Auvergne, INSERM, CHU, NEURO-DOL Basics & Clinical Pharmacology of Pain, F-63000 Clermont-Ferrand, France.ORCID 0000-0002-0873-6763
Inserm · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeAbdominal pain associated with low-grade inflammation is frequently encountered in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) during remission. Current treatments are not very effective and new therapeutic approaches are needed. The role of Ca EXPERIMENTAL APPROACH: Low doses of dextran sulfate sodium (DSS; 0.5%) were chronically administered to C57BL/6j mice in drinking water. Their inflammatory state was assessed by systemic and local measures of IL-6, myeloperoxidase, and lipocalin-2 using elisa. Colonic sensitivity was evaluated by the visceromotor responses to colorectal distension. Functional involvement of Ca KEY

resultsDSS induced low-grade inflammation associated with CHS in mice. Genetic or pharmacological inhibition of Ca CONCLUSIONS AND IMPLICATIONS: These results suggest that ethosuximide represents a promising drug reposition strategy and that inhibition of Ca

Indexed as

AnimalsBenzeneacetamidesBenzenesulfonamidesCalcium Channel BlockersCalcium Channels, T-TypeColonDextran SulfateDisease Models, AnimalEthosuximideGanglia, SpinalHeterocyclic Compounds, 2-RingInflammationInflammatory Bowel DiseasesInterleukin-6Irritable Bowel SyndromeMale2-(4-cyclopropylphenyl)-N-(1-(5-((2,2,2-trifluoroethyl)oxo)pyridin-2-yl)ethyl)acetamide4-chloro-2-fluoro-N-(2-fluorophenyl)-5-(hexahydropyrrolo(1,2-a)pyrazin-2(1H)-ylcarbonyl)benzenesulfonamideBenzeneacetamidesBenzenesulfonamidesCacna1h protein, mouseCalcium Channel BlockersCalcium Channels, T-TypeDextran SulfateEthosuximideHeterocyclic Compounds, 2-RingInterleukin-6interleukin-6, mousePyridinesSulfonamides

Identifiers

PMID30714145
PMCPMC6433640
OpenAlexW2912480304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.